Philipp Zimmer1,2, Sina Trebing3, Ursula Timmers-Trebing4, Alexander Schenk3, Rainer Paust5, Wilhelm Bloch3, Roland Rudolph6, Fiona Streckmann3,7,8, Freerk T Baumann9. 1. Department for Molecular and Cellular Sports Medicine, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany. p.zimmer@dshs-koeln.de. 2. Department for Physical Activity, Preventive Research and Cancer, German Cancer Research Center, Im Neuenheimer Feld, 280, Heidelberg, Germany. p.zimmer@dshs-koeln.de. 3. Department for Molecular and Cellular Sports Medicine, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany. 4. VGSU Essen, Association for Health Related Fitness and Sports Therapy at University Duisburg-Essen, Henri-Dunant-Str. 65, 45131, Essen, Germany. 5. Contilia Group, Institute for Psychosocial Medicine, Klara-Klopp-Weg 1, 45138, Essen, Germany. 6. Outpatient Tumor Centre Essen, Henricistr. 40, 45136, Essen, Germany. 7. Department of Sport, Exercise and Health, University of Basel, Birsstr. 320B, 4052, Basel, Switzerland. 8. Department of Medical Oncology, University Hospital of Basel, Petersgraben 4, 4031, Basel, Switzerland. 9. Department I of Internal Medicine, Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Abstract
PURPOSES: Physical activity is supposed to decrease mortality of colorectal cancer (CRC) and is suggested to reduce side-effects of the disease and its treatment. However, the knowledge about the influence of exercise interventions on patients suffering from CRC and metastasized CRC (mCRC) is still sparse. One frequently observed side effect in mCRC is chemotherapy-induced peripheral neuropathy (CIPN). This randomized controlled trial investigated the influence of a supervised exercise program on CIPN in mCRC. METHODS:Thirty patients (stage IV) undergoing outpatient palliative treatment including a median of 23.5 chemotherapy cycles of various regimens were randomly assigned to an intervention or control group (IG, n = 17; CG, n = 13). The IG participated in an eight-week supervised exercise program, including endurance, resistance and balance training (2×/week for 60 min) whereas the CG received written standard recommendations to obtain physical fitness. CIPN was assessed using the FACT/GOG-NTX questionnaire. Moreover, endurance capacity (6MWT), strength (h1RM) and balance (GGT-Reha) were evaluated before (t 0) and after (t 1) the intervention as well as after 4 weeks follow-up (t2). RESULTS:Neuropathic symptoms remained stable in the IG over time, while CIPN significantly worsened in the CG from t 0 to t 1 and t 0 to t 2. In contrast to the CG, the IG significantly improved in strength and balance function. Changes in CIPN correlated with changes in balance. CONCLUSIONS: This is the first investigation showing positive effects of a multimodal exercise program on CIPN, balance and strength on mCRC patients in a palliative setting, thereby consequently increasing patients` quality of life. The results support earlier findings stating a positive influence of balance exercise on CIPN.
RCT Entities:
PURPOSES: Physical activity is supposed to decrease mortality of colorectal cancer (CRC) and is suggested to reduce side-effects of the disease and its treatment. However, the knowledge about the influence of exercise interventions on patients suffering from CRC and metastasized CRC (mCRC) is still sparse. One frequently observed side effect in mCRC is chemotherapy-induced peripheral neuropathy (CIPN). This randomized controlled trial investigated the influence of a supervised exercise program on CIPN in mCRC. METHODS: Thirty patients (stage IV) undergoing outpatient palliative treatment including a median of 23.5 chemotherapy cycles of various regimens were randomly assigned to an intervention or control group (IG, n = 17; CG, n = 13). The IG participated in an eight-week supervised exercise program, including endurance, resistance and balance training (2×/week for 60 min) whereas the CG received written standard recommendations to obtain physical fitness. CIPN was assessed using the FACT/GOG-NTX questionnaire. Moreover, endurance capacity (6MWT), strength (h1RM) and balance (GGT-Reha) were evaluated before (t 0) and after (t 1) the intervention as well as after 4 weeks follow-up (t2). RESULTS:Neuropathic symptoms remained stable in the IG over time, while CIPN significantly worsened in the CG from t 0 to t 1 and t 0 to t 2. In contrast to the CG, the IG significantly improved in strength and balance function. Changes in CIPN correlated with changes in balance. CONCLUSIONS: This is the first investigation showing positive effects of a multimodal exercise program on CIPN, balance and strength on mCRC patients in a palliative setting, thereby consequently increasing patients` quality of life. The results support earlier findings stating a positive influence of balance exercise on CIPN.
Authors: Antoinetta J M Beijers; Floortje Mols; Vivianne C G Tjan-Heijnen; Catharina G Faber; Lonneke V van de Poll-Franse; Gerard Vreugdenhil Journal: Acta Oncol Date: 2014-11-24 Impact factor: 4.089
Authors: Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe Journal: Nat Rev Dis Primers Date: 2015-11-05 Impact factor: 52.329
Authors: F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz Journal: Ann Oncol Date: 2014-02 Impact factor: 32.976
Authors: J Matt McCrary; David Goldstein; David Wyld; Robert Henderson; Craig R Lewis; Susanna B Park Journal: J Cancer Surviv Date: 2019-06-06 Impact factor: 4.442
Authors: Paul Lennart Vollmers; Christoph Mundhenke; Nicolai Maass; Dirk Bauerschlag; Stefan Kratzenstein; Christoph Röcken; Thorsten Schmidt Journal: J Cancer Res Clin Oncol Date: 2018-06-25 Impact factor: 4.553
Authors: Mary Anne Lagmay Tanay; Jo Armes; Rona Moss-Morris; Anne Marie Rafferty; Glenn Robert Journal: J Cancer Surviv Date: 2021-03-12 Impact factor: 4.442
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: Ian R Kleckner; Charles Kamen; Jennifer S Gewandter; Nimish A Mohile; Charles E Heckler; Eva Culakova; Chunkit Fung; Michelle C Janelsins; Matthew Asare; Po-Ju Lin; Pavan S Reddy; Jeffrey Giguere; Jeffrey Berenberg; Shelli R Kesler; Karen M Mustian Journal: Support Care Cancer Date: 2017-12-14 Impact factor: 3.603
Authors: Alexander Haussmann; Nadine Ungar; Angeliki Tsiouris; Monika Sieverding; Joachim Wiskemann; Karen Steindorf Journal: Int J Behav Med Date: 2020-02
Authors: Susan G Dorsey; Ian R Kleckner; Debra Barton; Karen Mustian; Ann O'Mara; Diane St Germain; Guido Cavaletti; Suzanne C Danhauer; Dawn L Hershman; Andrea G Hohmann; Ahmet Hoke; Judith O Hopkins; Katherine P Kelly; Charles L Loprinzi; Howard L McLeod; Supriya Mohile; Judith Paice; Julia H Rowland; Daniela Salvemini; Rosalind A Segal; Ellen Lavoie Smith; Worta McCaskill Stevens; Michelle C Janelsins Journal: J Natl Cancer Inst Date: 2019-06-01 Impact factor: 13.506